197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)

K.N Moore,S Bouberhan,E Hamilton,J Liu,R.E O'Cearbhaill,D O'Malley,K Papadimitriou,D Schröder,E Van Nieuwenhuysen,S-Y Yoo,M Peterman,P Goncalves,T Schmidt,M Zhu,I Lowy,T Uldrick,E.A Miller

doi:10.1016/j.iotech.2022.100309

197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)

K.N Moore, S Bouberhan + Show 15 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100309

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
License type: cc-by-nc-nd

Affiliation: University of Oklahoma Health Sciences Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The Ohio State University, Antwerp University Hospital, Grand Charleroi Hospital

#Anti Programmed Cell Death-1 Monoclonal Antibody #Cemiplimab In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Mucin-16 is a cell surface glycoprotein that is overexpressed in epithelial OC. Ubamatamab (REGN4018) is a mucin-16 x cluster of differentiation 3 (MUC16xCD3) bispecific antibody that promotes T cell–mediated cytotoxicity by facilitating contact between cancer cells and T cells. Cemiplimab is an anti–programmed cell death-1 monoclonal antibody. The phase 1 study in patients with recurrent OC found ubamatamab monotherapy had an acceptable safety profile, durable clinical activity across a range of doses (as measured by RECIST and cancer antigen 125 [CA-125] response rates), and linear pharmacokinetics up to 800 mg weekly intravenous (IV)1.

Full Text